Nanoparticle drug delivery system for intravenous delivery of topoisomerase inhibitors

Joshua Williams, Rachael Lansdown, Robert Sweitzer, Marek Romanowski, Rachel LaBell, Rajan Ramaswami, Evan Unger

Research output: Contribution to journalArticle

113 Scopus citations

Abstract

Camptothecin-based drugs, because of their poor solubility and labile lactone ring, pose challenges for drug delivery. The purpose of this research was to develop a nanoparticle delivery system for camptotheca alkaloids. After initial investigations SN-38 was selected as the candidate camptotheca alkaloid for further development. Nanoparticles comprising SN-38, phospholipids and polyethylene glycol were developed and studied in vitro and in vivo. The SN-38 formulations were stable in human serum albumin and high lactone concentrations were observed even after 3 h. In vivo studies in nude mice showed prolonged half-life of the active (lactone form) drug in whole blood and increased efficacy compared to Camptosar® in a mouse xenograft tumor model.

Original languageEnglish (US)
Pages (from-to)167-172
Number of pages6
JournalJournal of Controlled Release
Volume91
Issue number1-2
DOIs
StatePublished - Aug 28 2003

Keywords

  • Efficacy
  • Formulation
  • Lactone stability
  • Nanoparticle
  • SN-38

ASJC Scopus subject areas

  • Pharmaceutical Science

Fingerprint Dive into the research topics of 'Nanoparticle drug delivery system for intravenous delivery of topoisomerase inhibitors'. Together they form a unique fingerprint.

  • Cite this